AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22416054 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 1794
Study 22416063 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-1® (500 mg/m2 for 7 days)
Number of subjects: 12
Study 22416063 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-1® (500 mg/m2 for 7 days) + paclitaxel (135 mg/m2 on day 6)
Number of subjects: 12
Study 22416063 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (135 mg/m2 on day 6)
Number of subjects: 12
Study 22416078 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone Replacement Therapy (GHRT)
Number of subjects: 0
Study 22416102 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRX gene mutations in tumors from adolescents and young adults (≥12 years)
Number of subjects: 104
Study 22416102 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRX gene mutations in tumors from children (18 months-<12 years)
Number of subjects: 104
Study 22416102 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRX gene mutations in tumors from infants (0-<18 months)
Number of subjects: 104
Study 22416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ATRX mutations with telomere length
Number of subjects: 104
Study 22416102 — intervention group
Group type: EXPERIMENTAL
Intervention: Association of ATRX mutations with ATRX protein presence
Number of subjects: 104
Study 22417933 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR treatment
Number of subjects: 156
Study 22419704 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT with cryopreserved CD34(+) progenitor cells
Number of subjects: 13
Study 22419719 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-cachexia (CC)
Number of subjects: 140
Study 22419719 — intervention group
Group type: COMPARATOR
Intervention: Cancer without cachexia (CNC)
Number of subjects: 140
Study 22419719 — intervention group
Group type: COMPARATOR
Intervention: Noncancer controls (CO)
Number of subjects: 140
Study 22419878 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine (single agent)
Number of subjects: 0
Study 22419878 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of perifosine and temsirolimus
Number of subjects: 0
Study 22420838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fever treatment strategy (acetaminophen 650 mg enterally every 6 hours for temperatures ≥ 38.3 °C; external cooling for temperatures ≥ 39.5 °C)
Number of subjects: 120
Study 22420838 — intervention group
Group type: COMPARATOR
Intervention: Permissive fever treatment strategy (acetaminophen 650 mg every 6 hours for temperatures ≥ 40.0 °C; external cooling for temperatures ≥ 40.5 °C)
Number of subjects: 120
Study 22420838 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive fever treatment strategy
Number of subjects: 120
Study 22420838 — intervention group
Group type: COMPARATOR
Intervention: Permissive fever treatment strategy
Number of subjects: 120
Study 22421192 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg daily, administered orally for 21 days on/seven days off in repeating cycles)
Number of subjects: 53
Study 22421192 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg daily)
Number of subjects: 53
Study 22421222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with plaque burden ≥ 70%
Number of subjects: 0
Study 22421222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with minimal luminal area ≤ 4.0 mm²
Number of subjects: 0
Study 22421222 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with IVUS-VH phenotype of thin-cap fibroatheroma
Number of subjects: 0
Study 22421222 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative rate of major adverse cardiovascular events
Number of subjects: 0
Study 22421223 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal segments
Number of subjects: 4234
Study 22421223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid segments
Number of subjects: 4234
Study 22421223 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal segments
Number of subjects: 4234
Study 22421223 — intervention group
Group type: COMPARATOR
Intervention: Left Main Coronary Artery (LMCA)
Number of subjects: 4234
Study 22421227 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpography and intravascular ultrasound virtual histology
Number of subjects: 114
Study 22421227 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpography
Number of subjects: 114
Study 22421227 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (stents and pharmacotherapy)
Number of subjects: 114
Study 22421228 — intervention group
Group type: EXPERIMENTAL
Intervention: MSCT (multislice computed tomography)
Number of subjects: 32
Study 22421230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 673
Study 22421230 — intervention group
Group type: EXPERIMENTAL
Intervention: Met Syn
Number of subjects: 673
Study 22421230 — intervention group
Group type: COMPARATOR
Intervention: Neither diabetes nor Met Syn
Number of subjects: 673
Study 22421230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and Met Syn
Number of subjects: 673
Study 22421230 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes and Met Syn with future MACE
Number of subjects: 673
Study 22421231 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD patients
Number of subjects: 646
Study 22421232 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 697
Study 22421232 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 697
Study 22421234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 697
Study 22421234 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PB70 lesions
Number of subjects: 697
Study 22421234 — intervention group
Group type: COMPARATOR
Intervention: Non-PB70 lesions
Number of subjects: 697
Study 22421235 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 NC lesion
Number of subjects: 697
Study 22421235 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 2 NC lesions
Number of subjects: 697
Study 22421235 — intervention group
Group type: COMPARATOR
Intervention: No NC lesions
Number of subjects: 697
Study 22421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with substantial lesion progression (SLP)
Number of subjects: 697
Study 22421236 — intervention group
Group type: COMPARATOR
Intervention: Nonculprit lesions without substantial lesion progression (SLP)
Number of subjects: 697
Study 22421236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonculprit lesions with SLP
Number of subjects: 697
Study 22421236 — intervention group
Group type: COMPARATOR
Intervention: Nonculprit lesions without SLP
Number of subjects: 697
Study 22421340 — intervention group
Group type: EXPERIMENTAL
Intervention: IL6R SNP (rs7529229)
Number of subjects: 133449
Study 22421340 — intervention group
Group type: COMPARATOR
Intervention: Tocilizumab (4-8 mg/kg every 4 weeks)
Number of subjects: 133449
Study 22421626 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 meter walking test
Number of subjects: 132
Study 22421626 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk test
Number of subjects: 132
Study 22421626 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (10 meter walking test)
Number of subjects: 132
Study 22421626 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (6 minute walk test)
Number of subjects: 132
Study 22422792 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical thrombosis prophylaxis (PTP) with low-molecular-weight heparin (LMWH)
Number of subjects: 5297
Study 22422826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 25 mg orally twice a day for 4 weeks (1 cycle), with dose escalation to 50 mg twice daily permitted for patients showing benefit.
Number of subjects: 38
Study 22422826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 38
Study 22423615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated and image-guided radiotherapy (IMRT-IGRT) by helical tomotherapy, delivering a dose of 50 Gy in fractions of 5 Gy.
Number of subjects: 24
Study 22423615 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical tomotherapy delivering 10 fractions of 5 Gy.
Number of subjects: 24
Study 22423615 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical tomotherapy
Number of subjects: 24
Study 22424004 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CCTA)
Number of subjects: 47
Study 22424004 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative quality initiatives including radiation dose reduction and appropriate CCTA use
Number of subjects: 47
Study 22424178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency ultrasound (LFU)
Number of subjects: 26
Study 22424178 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (short-acting bronchodilator)
Number of subjects: 26
Study 22424246 — intervention group
Group type: EXPERIMENTAL
Intervention: Lab-based risk score
Number of subjects: 122270
Study 22424246 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-based risk score
Number of subjects: 122270
Study 22424246 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between lab-based and BMI-based risk scores
Number of subjects: 122270
Study 22424246 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI-based risk score vs lab-based risk score
Number of subjects: 122270
Study 22424246 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance among lower estimated risk individuals
Number of subjects: 122270
Study 22424880 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1953
Study 22425095 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 50 mg with continuous daily dosing
Number of subjects: 30
Study 22425822 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia 1 xenon (70% for 1 hr)
Number of subjects: 15
Study 22425822 — intervention group
Group type: COMPARATOR
Intervention: Mild therapeutic hypothermia (33°C for 16 hrs)
Number of subjects: 15
Study 22425822 — intervention group
Group type: COMPARATOR
Intervention: Normothermic controls
Number of subjects: 15
Study 22426369 — intervention group
Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted H1N1 influenza vaccine (3.75µg HA)
Number of subjects: 100
Study 22426890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccination with IL-2, Cyclophosphamide, and Celecoxib
Number of subjects: 28
Study 22427378 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 200
Study 22427577 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline CSLO parameters
Number of subjects: 264
Study 22427577 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline SAP parameters
Number of subjects: 264
Study 22427577 — intervention group
Group type: EXPERIMENTAL
Intervention: RVM analyses of baseline CSLO and SAP parameters combined
Number of subjects: 264
Study 22427577 — intervention group
Group type: COMPARATOR
Intervention: CSLO Glaucoma Probability Score
Number of subjects: 264
Study 22427577 — intervention group
Group type: COMPARATOR
Intervention: SAP mean deviation (MD)
Number of subjects: 264
Study 22427577 — intervention group
Group type: COMPARATOR
Intervention: SAP pattern standard deviation (PSD)
Number of subjects: 264
Study 22427678 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 93
Study 22427678 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 93
Study 22427705 — intervention group
Group type: EXPERIMENTAL
Intervention: VHX trial (NCT01074905)
Number of subjects: 0
Study 22428786 — intervention group
Group type: EXPERIMENTAL
Intervention: High urinary phthalate concentration (measured as quartiles of phthalate metabolites)
Number of subjects: 725
Study 22429873 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient weight-loss program for children and adolescents (4 to 6 weeks duration) focusing on diet, physical activity, and behavior therapy.
Number of subjects: 1500
Study 22429873 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient weight-loss program follow-up assessments at 6 months, 1, 2, 5, and 10 years.
Number of subjects: 1500
Study 22429873 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood parameters and exercise capacity measurements at 5 and 10 year follow-ups.
Number of subjects: 1500
Study 22429908 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulants
Number of subjects: 1074
Study 22429908 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic SVT patients
Number of subjects: 1074
Study 22429908 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cancer or saphenofemoral junction involvement
Number of subjects: 1074
Study 22429908 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 1074
Study 22430088 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-positive patients before UCBT
Number of subjects: 143
Study 22430088 — intervention group
Group type: COMPARATOR
Intervention: MRD-negative patients before UCBT
Number of subjects: 143
Study 22430246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-balance-adjusted body mass index categorized as overweight
Number of subjects: 580
Study 22430246 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-balance-adjusted body mass index categorized as obese
Number of subjects: 580
Study 22431570 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101) administered in a dose-escalating fashion (3 per cohort, range 50/100-1200/2000 mg) for 8 × 21-day cycles
Number of subjects: 21
Study 22431570 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA101)
Number of subjects: 21
Study 22431702 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin (Arm 1a)
Number of subjects: 129
Study 22431702 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin (Arm 1b)
Number of subjects: 129
Study 22431702 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD plus carboplatin + Herceptin (Arm 2)
Number of subjects: 129
Study 22431777 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 1
Study 22431777 — intervention group
Group type: COMPARATOR
Intervention: Untreated tumors
Number of subjects: 1
Study 22432117 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine type 2 receptor (D2R) availability measured using positron emission tomography and [(18)F]fallypride
Number of subjects: 22
Study 22432687 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitex supplementation (3 capsules per day for 12 weeks)
Number of subjects: 30
Study 22433615 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral obesity treatment
Number of subjects: 684
Study 22434211 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic vitrectomy
Number of subjects: 150
Study 22434595 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted reproductive technology (ART)
Number of subjects: 65
Study 22434735 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) counselling sessions with a parent of the index child in Year 1 and one additional 'booster' visit in Year 2.
Number of subjects: 633
Study 22434735 — intervention group
Group type: EXPERIMENTAL
Intervention: Six MI counselling sessions from a trained dietician.
Number of subjects: 633
Study 22434735 — intervention group
Group type: COMPARATOR
Intervention: Usual care (standard health education materials).
Number of subjects: 633
Study 22434735 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent report of child's screen time, physical activity, intake of fruits and vegetables, and sugar-sweetened beverages.
Number of subjects: 633
Study 22436147 — intervention group
Group type: EXPERIMENTAL
Intervention: ART prescribed between baseline and 2 months
Number of subjects: 1605
Study 22436147 — intervention group
Group type: EXPERIMENTAL
Intervention: ART prescribed between 2 and 5 months
Number of subjects: 1605
Study 22436147 — intervention group
Group type: COMPARATOR
Intervention: PTB patients
Number of subjects: 1605
Study 22436147 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected patients not receiving ART
Number of subjects: 1605
Study 22436147 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infected patients already on ART at baseline
Number of subjects: 1605
Study 22436147 — intervention group
Group type: EXPERIMENTAL
Intervention: PTB patients (overall)
Number of subjects: 1605
Study 22436147 — intervention group
Group type: COMPARATOR
Intervention: Non-TB controls
Number of subjects: 1605
Study 22436661 — intervention group
Group type: EXPERIMENTAL
Intervention: H-1PV by intratumoral injection and administration into the walls of the tumor cavity during tumor resection
Number of subjects: 18
Study 22436661 — intervention group
Group type: EXPERIMENTAL
Intervention: H-1PV injected intravenously and into the surrounding brain tissue during tumor removal
Number of subjects: 18
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein intake (percentage energy)
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk intake (L/d)
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Android fat:gynoid fat ratio
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Android fat:body fat ratio
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gynoid fat:body fat ratio
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer counts
Number of subjects: 182
Study 22437560 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA
Number of subjects: 182
Study 22437872 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs)
Number of subjects: 0
Study 22437872 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody-drug conjugates
Number of subjects: 0
Study 22437872 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunomodulatory antibodies
Number of subjects: 0
Study 22437872 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic antibodies
Number of subjects: 0
Study 22438225 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (exercise, behavior, and nutrition therapy) for 1 year
Number of subjects: 100
Study 22438225 — intervention group
Group type: COMPARATOR
Intervention: Obese children
Number of subjects: 100
Study 22438225 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children with and without MetS or NAFLD
Number of subjects: 100
Study 22438229 — intervention group
Group type: EXPERIMENTAL
Intervention: Alipogene tiparvovec (AAV1-LPL(S447X)), administered at a dose of 1 × 10(12) genome copies per kilogram, intramuscularly.
Number of subjects: 0
Study 22438256 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab induction (200-2000 mg IV weekly for 4 weeks) followed by maintenance every 3 months for a maximum of 8 doses
Number of subjects: 22
Study 22438256 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab maintenance therapy
Number of subjects: 22
Study 22438931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (IL-1 receptor antagonist)
Number of subjects: 7
Study 22438987 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual (SL) administration of quadravalent HPV vaccine (n = 12)
Number of subjects: 18
Study 22438987 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of quadravalent HPV vaccine (n = 6)
Number of subjects: 18
Study 22439666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (single agent treatment)
Number of subjects: 0
Study 22439666 — intervention group
Group type: EXPERIMENTAL
Intervention: Folfiri-cetuximab regimen (after initial treatment with cetuximab)
Number of subjects: 0
Study 22439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory heart rate
Number of subjects: 360
Study 22439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory heart rate variability
Number of subjects: 360
Study 22439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical heart rate
Number of subjects: 360
Study 22439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Night/day systolic blood pressure ratio
Number of subjects: 360
Study 22439900 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 360
Study 22440484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower EROS scores (Environment Rewards Observation Scale)
Number of subjects: 244
Study 22440484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower self-efficacy (Modified Lorig Chronic Disease Self-Management Scale)
Number of subjects: 244
Study 22440484 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (International Physical Activity Questionnaire)
Number of subjects: 244
Study 22440496 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5011
Study 22441650 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-NP+M1 vaccine
Number of subjects: 22
Study 22441650 — intervention group
Group type: COMPARATOR
Intervention: No vaccination (control)
Number of subjects: 22
Study 22442048 — intervention group
Group type: EXPERIMENTAL
Intervention: Square area measurements of orbital apex crowding calculated with multidetector CT (MDCT)
Number of subjects: 56
Study 22442048 — intervention group
Group type: EXPERIMENTAL
Intervention: CIs at 12 mm, 18 mm, and 24 mm
Number of subjects: 56
Study 22442048 — intervention group
Group type: COMPARATOR
Intervention: Subjective grading of orbital crowding
Number of subjects: 56
Study 22442048 — intervention group
Group type: COMPARATOR
Intervention: Intracranial fat prolapse
Number of subjects: 56
Study 22442161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy by experienced colonoscopists with varying CME meetings attended
Number of subjects: 12134
Study 22442161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy by colonoscopists with different instrument generations used
Number of subjects: 12134
Study 22442161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with varying annual CME meetings attended by physicians
Number of subjects: 12134
Study 22442161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with withdrawal times between 6-11 minutes
Number of subjects: 12134
Study 22442161 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy with varying annual screening case volumes
Number of subjects: 12134